Catalog No.: PC-43297Not For Human Use, Lab Use Only.
TP-0903 (Dubermatinib, TP0903) is a potent, selective, orally bioavailable Axl inhibitor with IC50 of 27 nM inhibits cell viability of pncreactic cancer cells (PSN1) with IC50 of 6 nM.
TP-0903 (Dubermatinib, TP0903) is a potent, selective, orally bioavailable Axl inhibitor with IC50 of 27 nM inhibits cell viability of pncreactic cancer cells (PSN1) with IC50 of 6 nM.
TP-0903 also strongly inhibits related TAM family members MER and TYRO3, Aurora A/B (IC50=3.0/12.4 nM), JAK2, ALK, ABL1, and CHEK1 in a panel of 75 kinases (11/75 >50% inhibition at 200 nM)。
TP-0903 induces robust levels of apoptosis in CLL B-cells from all the CLL patients with mean LD50 of 0.14 uM; inhibits neuroblastoma cell growth, reduces NB cells intravasation in vitro and in vivo and enhances the sensitivity to conventional chemotherapy.
